Clinical research
Pfizer and BioNTech indicate that this data, along with preclinical data and additional data being generated, will be leveraged to choose a dose level and pick the best vaccine candidate out of the several being evaluated.
Of the 40 patients who responded who had end-of-treatment biopsies, 48% showed at least a one-stage improvement in fibrosis without worsening of NAFLD activity score and 28% demonstrated at least a two-stage improvement in fibrosis.
INO-4800 is one of the experimental vaccines included in the U.S. government’s Operation Warp Speed that has a goal of having a vaccine available by January 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.
It was a busy week for clinical trial updates. Here’s a look.
With Moderna on the precipice of launching its Phase III trial of 30,000 people for its COVID-19 vaccine, mRNA-1273, it is ramping up manufacturing capabilities.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.
PRESS RELEASES